Preetha Muthusamy, MD
Neuromuscular Medicine · Warren, OHNPI 1205001161
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 73.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $181 and has fallen 73.9% since, to $47 in 2025.
Across 26 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$383
- Amgen$47
- Lilly USA, LLC$43
- Novartis$25
- Supernus Pharmaceuticals, Inc.$22
What the payments were for
- Food & beverage$47491%
- Education$479%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $383 |
| Amgen | 1 | $47 |
| Lilly USA, LLC | 2 | $43 |
| Novartis | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 2 | $22 |
How this compares
Too few neuromuscular medicine providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 23 | $258,510 |
| Aimovig AutoinjectorErenumab-Aooe | 136 | $109,986 |
| Nurtec OdtRimegepant Sulfate | 76 | $92,319 |
| QuliptaAtogepant | 22 | $25,278 |
| NeuproRotigotine | 18 | $22,860 |
| Emgality PenGalcanezumab-Gnlm | 29 | $20,588 |
| UbrelvyUbrogepant | 15 | $19,598 |
| RytaryCarbidopa/Levodopa | 18 | $16,189 |
| Lacosamide | 92 | $11,864 |
| Repatha SyringeEvolocumab | 15 | $9,194 |
| Dalfampridine ErDalfampridine | 18 | $8,088 |
| Memantine Hcl | 304 | $8,065 |
| Entacapone | 35 | $6,629 |
| Memantine Hcl ErMemantine Hcl | 62 | $6,379 |
| SavellaMilnacipran Hcl | 12 | $6,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy, Savella | $383 | $50,91249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Ohioon file to place this against a meaningful peer group, so we don't.
Other neuromuscular medicine in Warren
- Preston EiblingDublin$15K
- Komal SawlaniCleveland$2K
- Robert AdamsCleveland$572
- Georgette DibCleveland$445
- Christelle HaddadCleveland$220
- Benjamin ClaytorCleveland$211
- Alexander MorrisonColumbus$200
- Danielle RichardsCleveland$156
- Robert MarquardtCleveland$154
- Mahmood ShbebCleveland$154
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.